CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications
- Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain
Abstract
Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in tumorigenesis and clinical relevance remain largely unclear. Here we developed CNApp, a web-based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma, and predicts colon cancer molecular subtypes and microsatellite instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp facilitates CNA-driven research by providing a unique framework to identify relevant clinical implications. CNApp is hosted at https://tools.idibaps.org/CNApp/.
Data availability
Data and plots presented in the submission were generated by using our CNApp tool. Source code and additional files can be found at GitHub (https://github.com/ait5/CNApp).
Article and author information
Author details
Sebastià Franch-Expósito
Funding
CIBEREHD
- Sebastià Franch-Expósito
Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (GCB13131592CAST)
- Juan José Lozano
- Antoni Castells
- Sergi Castellvi-Bel
- Jordi Camps
European Commission /Horizon 2020 Program (HEPCAR Ref. 667273-2)
- Josep Maria Llovet
U.S. Department of Defense (CA150272P3)
- Josep Maria Llovet
National Cancer Institute (P30-CA196521)
- Josep Maria Llovet
Samuel Waxman Cancer Research Foundation
- Josep Maria Llovet
Spanish National Health Institute (SAF2016-76390)
- Josep Maria Llovet
Generalitat de Catalunya/AGAUR (SGR-1162)
- Josep Maria Llovet
Generalitat de Catalunya/AGAUR (SGR-1358)
- Josep Maria Llovet
European Regional Development Fund (PI14/00783)
- Marcos Díaz-Gay
- Juan José Lozano
- Antoni Castells
- Sergi Castellvi-Bel
- Jordi Camps
European Regional Development Fund (PI17/01304)
- Marcos Díaz-Gay
- Juan José Lozano
- Antoni Castells
- Sergi Castellvi-Bel
- Jordi Camps
Generalitat de Catalunya (AGAUR 2016BP00161)
- Laia Bassaganyas
European Regional Development Fund (PI17/00878)
- Marcos Díaz-Gay
- Juan José Lozano
- Antoni Castells
- Sergi Castellvi-Bel
- Jordi Camps
Generalitat de Catalunya (2017 SGR 21)
- Juan José Lozano
- Antoni Castells
- Sergi Castellvi-Bel
- Jordi Camps
Generalitat de Catalunya (2017 SGR 653)
- Juan José Lozano
- Antoni Castells
- Sergi Castellvi-Bel
- Jordi Camps
Generalitat de Catalunya (AGAUR 2018FI B1_00213)
- Marcos Díaz-Gay
Spanish National Health Institute (FPI BES-2017-081286)
- Roger Esteban-Fabró
European Comission (PCIG11-GA-2012-321937)
- Juan José Lozano
- Antoni Castells
- Sergi Castellvi-Bel
- Jordi Camps
European Regional Development Fund (CP13/00160)
- Marcos Díaz-Gay
- Juan José Lozano
- Antoni Castells
- Sergi Castellvi-Bel
- Jordi Camps
CERCA Program
- Juan José Lozano
- Antoni Castells
- Josep Maria Llovet
- Sergi Castellvi-Bel
- Jordi Camps
Generalitat de Catalunya (2017 SGR 1035)
- Juan José Lozano
- Antoni Castells
- Sergi Castellvi-Bel
- Jordi Camps
PERIS Generalitat de Catalunya (SLT002/16/00398)
- Juan José Lozano
- Antoni Castells
- Sergi Castellvi-Bel
- Jordi Camps
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- C Daniela Robles-Espinoza, International Laboratory for Human Genome Research, Mexico
Version history
- Received: July 17, 2019
- Accepted: January 14, 2020
- Accepted Manuscript published: January 15, 2020 (version 1)
- Version of Record published: February 10, 2020 (version 2)
Copyright
© 2020, Franch-Expósito et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 9,259
- views
-
- 473
- downloads
-
- 47
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications
eLife 9:e50267.
https://doi.org/10.7554/eLife.50267
Further reading
-
- Computational and Systems Biology
- Evolutionary Biology
A comprehensive census of McrBC systems, among the most common forms of prokaryotic Type IV restriction systems, followed by phylogenetic analysis, reveals their enormous abundance in diverse prokaryotes and a plethora of genomic associations. We focus on a previously uncharacterized branch, which we denote coiled-coil nuclease tandems (CoCoNuTs) for their salient features: the presence of extensive coiled-coil structures and tandem nucleases. The CoCoNuTs alone show extraordinary variety, with three distinct types and multiple subtypes. All CoCoNuTs contain domains predicted to interact with translation system components, such as OB-folds resembling the SmpB protein that binds bacterial transfer-messenger RNA (tmRNA), YTH-like domains that might recognize methylated tmRNA, tRNA, or rRNA, and RNA-binding Hsp70 chaperone homologs, along with RNases, such as HEPN domains, all suggesting that the CoCoNuTs target RNA. Many CoCoNuTs might additionally target DNA, via McrC nuclease homologs. Additional restriction systems, such as Type I RM, BREX, and Druantia Type III, are frequently encoded in the same predicted superoperons. In many of these superoperons, CoCoNuTs are likely regulated by cyclic nucleotides, possibly, RNA fragments with cyclic termini, that bind associated CARF (CRISPR-Associated Rossmann Fold) domains. We hypothesize that the CoCoNuTs, together with the ancillary restriction factors, employ an echeloned defense strategy analogous to that of Type III CRISPR-Cas systems, in which an immune response eliminating virus DNA and/or RNA is launched first, but then, if it fails, an abortive infection response leading to PCD/dormancy via host RNA cleavage takes over.
-
- Computational and Systems Biology
Imputing data is a critical issue for machine learning practitioners, including in the life sciences domain, where missing clinical data is a typical situation and the reliability of the imputation is of great importance. Currently, there is no canonical approach for imputation of clinical data and widely used algorithms introduce variance in the downstream classification. Here we propose novel imputation methods based on determinantal point processes (DPP) that enhance popular techniques such as the multivariate imputation by chained equations and MissForest. Their advantages are twofold: improving the quality of the imputed data demonstrated by increased accuracy of the downstream classification and providing deterministic and reliable imputations that remove the variance from the classification results. We experimentally demonstrate the advantages of our methods by performing extensive imputations on synthetic and real clinical data. We also perform quantum hardware experiments by applying the quantum circuits for DPP sampling since such quantum algorithms provide a computational advantage with respect to classical ones. We demonstrate competitive results with up to 10 qubits for small-scale imputation tasks on a state-of-the-art IBM quantum processor. Our classical and quantum methods improve the effectiveness and robustness of clinical data prediction modeling by providing better and more reliable data imputations. These improvements can add significant value in settings demanding high precision, such as in pharmaceutical drug trials where our approach can provide higher confidence in the predictions made.
